[PDF] Top 20 <p>Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle</p>
Has 10000 "<p>Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle</p>" found on our website. Below are the top 20 most common "<p>Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle</p>".
<p>Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle</p>
... with PD-1 blockade, the tumor growth of IDO knockout mice was signi fi cantly delayed, and the overall survival rate was improved compared with wild type ...with PD-1/PD-L1 ... See full document
12
Host expression of PD L1 determines efficacy of PD L1 pathway blockade–mediated tumor regression
... host PD-L1 and PD-1 pathway in PD-L1 and PD-1 blockade ...tissue PD-L1 expression (including PD-L1 expression in all types of ... See full document
12
Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
... of PD-1/PD-L1 blockade therapy into the tumor microenvironment, and largely sup- ports the concept that PD-L1 acts as a molecular shield on both tumor cells and host ... See full document
8
The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients
... function. PD-1 coordinately upregulated the expression of transcription factor ATF-like (BATF) which was sufficient to impair T cell proliferation and cytokine secretion ...reduced PD-1 ... See full document
12
Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition
... The mechanism of HBV reactivation induced by anti- PD-1/PD-L1 therapy is ...The PD-1/PD-L1 axis is a critical pathway for maintaining immune homeostasis ... See full document
10
Contribution of NK cells to immunotherapy mediated by PD 1/PD L1 blockade
... of PD-L1 in vitro, which was strongly upregulated by IFN-γ (Figure ...of PD-1 inhibition in this tumor model, we generated a PD-L1–deficient variant of CT26 by targeting the Pdl1 ... See full document
16
Baseline T cell dysfunction by single cell network profiling in metastatic breast cancer patients
... therapy resistance [3, 4] TGFβ has broad immune sup- pressive activity ...breast cancer models that neutralization of TGFβ was required for the radiotherapy-induced activation of tumor-specific CD8 T cells ... See full document
8
Oncolytic virus and PD-1/PD-L1 blockade combination therapy
... against cancer cells and may thus be viewed as a form of ...antitumor immunity can be effective, the dynamic nature of the immunosuppressive tumor microenviron- ment presents significant hurdles to the ... See full document
13
PD L1 on host cells is essential for PD L1 blockade–mediated tumor regression
... National Cancer Insti- tute grants CA141975, Texas CPRIT grant RR150072, and grants from the Chinese Academy of Sciences (XDA09030303) and the Chinese Ministry of Science and Technology (2012ZX10002006 and ... See full document
10
Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
... anti-tumor immunity after administration of anti-PD-1, an immune checkpoint ...[27]. PD-L1 expression on tumor cells and immune cells has been shown to enrich for response to ... See full document
5
Targeting PD-1/PD-L1 in lung cancer: current perspectives
... ligands PD-L1 (also known as B7-H1 or CD274) and PD-L2 (also known as B7-DC or ...CD273). PD-1 is present in T activated cells, tumor-infiltrating T-cells, B-cells, monocytes, and NK ... See full document
16
T cell Bim levels reflect responses to anti–PD-1 cancer therapy
... death 1 (PD-1) pathway has been found to play a crucial role in tumor-induced immu- nosuppression in melanoma, lung cancer, renal cell cancer, and other malignancies and is an ... See full document
15
Induction of T Cell Immunity Overcomes Resistance to Pd-1 and Ctla-4 Blockade and Improves Survival in Pancreatic Cancer
... of PD-1 and PD-L1 in the KPC tumor microenvironment, I chose to test our hypothesis using the αPD-1 ...Neither PD-1 alone nor αCD40/chemotherapy significantly improved ... See full document
152
<p>The Role Of PD-1/PD-L1 Axis In Treg Development And Function: Implications For Cancer Immunotherapy</p>
... Treg is a highly immunosuppressive subpopulation of CD4 + T cells, characterized by transcription factor fork- head box P3 (Foxp3). Tregs were previously identi fi ed as CD4 + CD25 + T cells and are con fi rmed to inhibit ... See full document
9
Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy
... of PD-1:PD-L1 blockade occurring outside of the tumor microenvironment due to heterogeneity of PD-L1 expression in cancer lesions, which is not always correctly ... See full document
12
A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses
... The combination of olaparib and cediranib, a VEGFR1–3 inhibitor, has been demonstrated to be clin- ically superior to olaparib monotherapy in recurrent platinum-sensitive ovarian cancer [8]. We extended this ... See full document
8
Clinical heterogeneity of hypophysitis secondary to PD-1/PD-L1 blockade: insights from four cases
... starting PD-1/PD-L1 blockade, and only after 1 week in one patient treated with double blockade PD-1 and ...cases 1 and ... See full document
6
PD-L1 expression in human cancers and its association with clinical outcomes
... lung cancer; RFS, relapse-free survival; VPSI, visceral pleural surface invasion; OS, overall survival; TNM, tumor–node–metastasis; CRC, colorectal cancer; mAb, monoclonal antibody; MMR, mismatch repair; ... See full document
17
The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies
... of PD-1 and PD-L1 expression character- istics in leukemia and lymphomas with defective T-cell immune responses have implications for the design of T- cell-based cancer immunotherapy, ... See full document
6
Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November–2 December, 2017, Naples, Italy)
... A melanoma-specific gene panel, known as MelAr- ray, has been developed based on the WES at USZ and Yale University. This panel is composed of 195 mela- noma mutant genes [single-nucleotide variants (SNVs), copy-number ... See full document
13
Related subjects